222 related articles for article (PubMed ID: 34249004)
1. Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based
Richardson S; Medhavi F; Tanner T; Lundy S; Omosun Y; Igietseme JU; Carroll D; Eko FO
Front Immunol; 2021; 12():698737. PubMed ID: 34249004
[TBL] [Abstract][Full Text] [Related]
2. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses.
Pais R; Omosun Y; Igietseme JU; Fujihashi K; Eko FO
Front Immunol; 2019; 10():1577. PubMed ID: 31333682
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.
Pan Q; Pais R; Ohandjo A; He C; He Q; Omosun Y; Igietseme JU; Eko FO
Vaccine; 2015 Apr; 33(15):1865-72. PubMed ID: 25698486
[TBL] [Abstract][Full Text] [Related]
4. A novel cold-chain free VCG-based subunit vaccine protects against
Richardson S; Bell CR; Medhavi F; Tanner T; Lundy S; Omosun Y; Igietseme JU; Eko FO
Front Immunol; 2023; 14():1243743. PubMed ID: 37915580
[No Abstract] [Full Text] [Related]
5.
Pan Q; Zhang Q; Chu J; Pais R; Liu S; He C; Eko FO
Front Cell Infect Microbiol; 2017; 7():514. PubMed ID: 29326885
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.
Eko FO; Lubitz W; McMillan L; Ramey K; Moore TT; Ananaba GA; Lyn D; Black CM; Igietseme JU
Vaccine; 2003 Apr; 21(15):1694-703. PubMed ID: 12639492
[TBL] [Abstract][Full Text] [Related]
7. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.
Ekong EE; Okenu DN; Mania-Pramanik J; He Q; Igietseme JU; Ananaba GA; Lyn D; Black C; Eko FO
FEMS Immunol Med Microbiol; 2009 Mar; 55(2):280-91. PubMed ID: 19040663
[TBL] [Abstract][Full Text] [Related]
8. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes.
Macmillan L; Ifere GO; He Q; Igietseme JU; Kellar KL; Okenu DM; Eko FO
FEMS Immunol Med Microbiol; 2007 Feb; 49(1):46-55. PubMed ID: 17094789
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.
Eko FO; Okenu DN; Singh UP; He Q; Black C; Igietseme JU
Vaccine; 2011 May; 29(21):3802-10. PubMed ID: 21421002
[TBL] [Abstract][Full Text] [Related]
10. Induction of immune memory by a multisubunit chlamydial vaccine.
Eko FO; Ekong E; He Q; Black CM; Igietseme JU
Vaccine; 2011 Feb; 29(7):1472-80. PubMed ID: 21184858
[TBL] [Abstract][Full Text] [Related]
11. Rectal administration of a chlamydial subunit vaccine protects against genital infection and upper reproductive tract pathology in mice.
Pais R; Omosun Y; He Q; Blas-Machado U; Black C; Igietseme JU; Fujihashi K; Eko FO
PLoS One; 2017; 12(6):e0178537. PubMed ID: 28570663
[TBL] [Abstract][Full Text] [Related]
12. A novel recombinant multisubunit vaccine against Chlamydia.
Eko FO; He Q; Brown T; McMillan L; Ifere GO; Ananaba GA; Lyn D; Lubitz W; Kellar KL; Black CM; Igietseme JU
J Immunol; 2004 Sep; 173(5):3375-82. PubMed ID: 15322201
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge.
Zuo Z; Zou Y; Li Q; Guo Y; Zhang T; Wu J; He C; Eko FO
Sci Rep; 2021 May; 11(1):10389. PubMed ID: 34001988
[TBL] [Abstract][Full Text] [Related]
14. Differential miRNA Profiles Correlate With Disparate Immunity Outcomes Associated With Vaccine Immunization and Chlamydial Infection.
Howard S; Richardson S; Benyeogor I; Omosun Y; Dye K; Medhavi F; Lundy S; Adebayo O; Igietseme JU; Eko FO
Front Immunol; 2021; 12():625318. PubMed ID: 33692799
[TBL] [Abstract][Full Text] [Related]
15. The
Verma R; Sahu R; Dixit S; Duncan SA; Giambartolomei GH; Singh SR; Dennis VA
Front Immunol; 2018; 9():2369. PubMed ID: 30374357
[TBL] [Abstract][Full Text] [Related]
16. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.
Yu H; Karunakaran KP; Jiang X; Brunham RC
Vaccine; 2014 Aug; 32(36):4672-80. PubMed ID: 24992718
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine.
Ifere GO; He Q; Igietseme JU; Ananaba GA; Lyn D; Lubitz W; Kellar KL; Black CM; Eko FO
J Microbiol Immunol Infect; 2007 Jun; 40(3):188-200. PubMed ID: 17639158
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
